An Open-Label, Multi-Center, Phase IB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin (Plus a Single Pre-Treatment Dose of Obinutuzumab) in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
This is an open-label, single arm, multicenter, dose finding, Phase Ib study in order to
assess the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D) for this
combination treatment and to evaluate the general safety, tolerability, pharmacokinetic (PK),
pharmacodynamic, and preliminary anti-tumor activity of this combination treatment in adult
This study includes an additional open-label imaging feasibility sub-study using a tracer in
adult participants with relpased/refractory B-cell non-Hodgkin's lymphoma to image
CD8+T-cells at baseline and after treatment with glofitamab, including pre-treatment with
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.